WuXi AppTec posts lower profits but avoids more share price pain
The pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit Key Takeaways: U.S.…
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
CHINA BULLETIN: Manufacturing Déjà Vu
In this week’s issue European gloom, a new chip fund and foreign law firms flee Shanghai. On a scale of 1 to 100, we give the week a 45 for…
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe…
China-focused Tigermed staves off biopharma gloom
Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks Key Takeaways: Tigermed…
InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
FAST NEWS: BlackRock boosts stake in battered WuXi AppTec
The latest: Asset management company BlackRock Inc. purchased 618,000 Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on March 26, raising its stake in the drug outsourcing services company from…
Recent Articles
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK
603259.SHG
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK
2359.HK
2268.HK
China-focused Tigermed staves off biopharma gloom
3347.HK
300347.SHE
FAST NEWS: BlackRock boosts stake in battered WuXi AppTec
2359.HK
603259.SHG
RELATED ARTICLES
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG -
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK
-
China-focused Tigermed staves off biopharma gloom
3347.HK 300347.SHE
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
- CHINA BULLETIN: Manufacturing Déjà Vu
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
